Literature DB >> 15086870

Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle.

P R Strege1, S Evangelista, G L Lyford, M G Sarr, G Farrugia.   

Abstract

Otilonium bromide (OB) is used as an intestinal antispasmodic. The mechanism of action of OB is not completely understood. As Ca(2+) entry into intestinal smooth muscle is required to trigger contractile activity, our hypothesis was that OB blocked Ca(2+) entry through L-type Ca(2+) channels. Our aim was to determine the effects of OB on Ca(2+), Na(+) and K(+) ion channels in human jejunal circular smooth muscle cells and on L-type Ca(2+) channels expressed heterologously in HEK293 cells. Whole cell currents were recorded using standard patch clamp techniques. Otilonium bromide (0.09-9 micromol L(-1)) was used as this reproduced clinical intracellular concentrations. In human circular smooth muscle cells, OB inhibited L-type Ca(2+) current by 25% at 0.9 micromol L(-1) and 90% at 9 micromol L(-1). Otilonium bromide had no effect on Na(+) or K(+) currents. In HEK293 cells, 1 micromol L(-1) OB significantly inhibited the expressed L-type Ca(2+) channels. Truncation of the alpha(1C) subunit C and N termini did not block the inhibitory effects of OB. Otilonium bromide inhibited Ca(2+) entry through L-type Ca(2+) at concentrations similar to intestinal tissue levels. This effect may underlie the observed muscle relaxant effects of the drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086870     DOI: 10.1111/j.1365-2982.2004.00517.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  16 in total

1.  Otilonium bromide as spasmolytic during endoscopic retrograde cholangiopancreatography.

Authors:  Ömer Karahan; Barış Sevinç; Ahmet Okuş; Serden Ay; Nergis Aksoy
Journal:  Surg Endosc       Date:  2014-11-01       Impact factor: 4.584

2.  Targeting ion channels for the treatment of gastrointestinal motility disorders.

Authors:  Arthur Beyder; Gianrico Farrugia
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

3.  Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.

Authors:  G Cipriani; S J Gibbons; S A Saravanaperumal; J Malysz; L Sha; J H Szurszewski; D R Linden; S Evangelista; M S Faussone-Pellegrini; M G Vannucchi; G Farrugia
Journal:  Neurogastroenterol Motil       Date:  2015-04-30       Impact factor: 3.598

Review 4.  Irritable bowel syndrome.

Authors:  Antonella Spinelli
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

5.  T-type Ca(2+) channel modulation by otilonium bromide.

Authors:  Peter R Strege; Lei Sha; Arthur Beyder; Cheryl E Bernard; Edward Perez-Reyes; Stefano Evangelista; Simon J Gibbons; Joseph H Szurszewski; Gianrico Farrugia
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-04       Impact factor: 4.052

6.  Effects of the Calcium Channel Blocker Otilonium Bromide on Seizure Activity in Rats With Pentylenetetrazole-Induced Convulsions.

Authors:  Arife Erdogan; Mumin Alper Erdogan; Ozum Atasoy; Oytun Erbas
Journal:  Neurochem Res       Date:  2021-04-03       Impact factor: 3.996

Review 7.  Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.

Authors:  Jakub Rychter; Francisco Espín; Diana Gallego; Patri Vergara; Marcel Jiménez; Pere Clavé
Journal:  Therap Adv Gastroenterol       Date:  2014-07       Impact factor: 4.409

Review 8.  New and Investigational Agents for Irritable Bowel Syndrome.

Authors:  Akhilesh Wadhwa; Michael Camilleri; Madhusudan Grover
Journal:  Curr Gastroenterol Rep       Date:  2015-12

Review 9.  IBS and the role of otilonium bromide.

Authors:  Guy Boeckxstaens; Enrico S Corazziari; Fermín Mearin; Jan Tack
Journal:  Int J Colorectal Dis       Date:  2012-11-22       Impact factor: 2.571

10.  Irritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity.

Authors:  Ashley L Cunningham; Orhi Esarte Palomero; Bradley J Voss; M Stephen Trent; Bryan W Davies
Journal:  Antimicrob Agents Chemother       Date:  2021-07-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.